Sylvia D. Aruffo

Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA.

Corvita Corporation is a development stage company engaged primarily in research and development of new medical devices and related biomaterials for treatment of late stage vascular disease. The company is sponsoring two FDA controlled, randomized prospective trials in the US for its peripheral grafts and AV access grafts, both of which are approved for sale in the European Common Market. In addition, Corvita is conducting clinical tests in Europe and plans to begin FDA controlled clinical studies in the US of the Corvita Endoluminal Graft, a new less invasive product for lower cost treatment of vascular trauma, vascular occlusive disease and aneurysmal disease. The majority of the company's activities in FY 96 will be focused on development and testing of Corvita Endoluminal Grafts.

The Capital Group Cos., Inc. provides investment management services. The firm manages and underwrites mutual funds in the American Funds family group and provides other financial services. It serves the institutions, consultants, financial advisors, intermediaries, and individual investors. The company was founded by Jonathan Bell Lovelace in 1931 and is headquartered in Los Angeles, CA.

PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY.

Ponce De Leon Health engages in the provision of medical services. The company was founded by Norman R. Weldon and Thomas D. Weldon and is headquartered in Ireland.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Medivance, Inc. develops, manufactures and markets therapeutic temperature management products. The company was founded in 1998 and is headquartered in Louisville, CO.

Enable Injections, Inc. develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The company was founded by Michael D. Hooven in February 2010 and is headquartered in Cincinnati, OH.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Zurex Pharma, Inc. provides safe and effective anti-microbial products. Its products include ZuraPrep, a pre-surgical skin preparation for the prevention of SSI; ZurAsept, an antimicrobial and antithrombotic catheter solution to reduce CRBSI; and ZuraGard that prevents extra-luminal or exit site wound CRBSI. The company was founded in April 2008 and is headquartered in Middleton, WI.

Ash Access Technology, Inc. develops catheters, antimicrobials, vascular access devices and other catheter-related products and services. Its products include zuragen Injection, zuraprep, centros and pipeline. The firm engages in the development and commercialization of proprietary technologies and devices to treat and prevent the clinical consequences of diseases and disorders related to vascular access. The company was founded by Robert B. Truitt and Stephen R. Ash in 1983 and is headquartered in Lafayette, IN.